Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 20/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | TEC | P42680 | 1/20 | 0.68 |
| ▸ | TXK | P42681 | 1/20 | 0.68 |
| ▸ | BMX | P51813 | 1/20 | 0.68 |
| ▸ | JAK3 | P52333 | 1/20 | 0.68 |
| ▸ | ITK | Q08881 | 1/20 | 0.68 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19715416 | 0.92 | BTK (1.00) | BTKJAK2LCKTECTXK | |
| SCHEMBL19715446 | 0.92 | BTK (1.00) | BTKJAK2LCKTECTXK | |
| SCHEMBL19715295 | 0.88 | BTK (1.00) | BTKJAK2LCKTECTXK | |
| SCHEMBL19715397 | 0.88 | BTK (1.00) | BTKJAK2 | |
| SCHEMBL19715431 | 0.88 | BTK (1.00) | BTKJAK2 | |
| SCHEMBL21509095 | 0.87 | BTK (0.80) | BTKJAK2LCKTECTXK | |
| SCHEMBL19715400 | 0.85 | BTK (1.00) | BTK | |
| SCHEMBL19715335 | 0.84 | BTK (1.00) | BTKJAK2LCKTECTXK | |
| SCHEMBL19715386 | 0.81 | BTK (1.00) | BTKJAK2LCKTECTXK | |
| SCHEMBL19715435 | 0.81 | BTK (1.00) | BTKJAK2LCKTECTXK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3209651-B9 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2020-05-20 | — | — | EP | claimed |
| EP-3209651-B1 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | claimed |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-21 | — | — | US | claimed |
| US-11053197-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053197-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-06 | — | — | US | disclosed |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | Organization Name: BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-13 | — | — | US | disclosed |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | Organization Name: BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-13 | — | — | US | disclosed |
| US-10676434-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| US-10676434-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-09 | — | — | US | disclosed |
| EP-3209651-B9 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3209651-B1 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3209651-B1 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2019-10-23 | — | — | EP | disclosed |
| US-20190225583-A1 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2019-07-25 | — | — | US | disclosed |
| US-20190225583-A1 | CARBAZOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2019-07-25 | — | — | US | disclosed |
| US-10266491-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266491-B2 | Carbazole derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10266491-B2 | Carbazole derivatives | BTK, SYK, JAK2 | BTK 1/4885JAK2 3/4885LCK 49/4885 |
| US-10676434-B2 | Carbazole derivatives | BTK, SYK, JAK2 | BTK 1/4885JAK2 3/4885LCK 52/4885 |
| US-20170362176-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | BTK 1/4885JAK2 3/4885LCK 49/4885 |
| US-11053197-B2 | Carbazole derivatives | BTK, SYK, JAK2 | BTK 1/4885JAK2 3/4885LCK 52/4885 |
| US-20190225583-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | BTK 1/4885JAK2 3/4885LCK 52/4885 |
| US-20200255377-A1 | CARBAZOLE DERIVATIVES | BTK, SYK, JAK2 | BTK 1/4885JAK2 3/4885LCK 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.